Details for Patent: 11,865,098

« Back to Dashboard

Which drugs does patent 11,865,098 protect, and when does it expire?

Patent 11,865,098 protects SUNOSI and is included in one NDA.

This patent has eighteen patent family members in twelve countries.

Summary for Patent: 11,865,098

Title:	Methods and compositions for treating excessive sleepiness
Abstract:	The present invention relates to carbamoyl phenylalaninol compounds and methods of using the same to treat disorders. The invention further relates to the development of methods for treating excessive sleepiness in a subject, e.g., due to narcolepsy or obstructive sleep apnea, with the surprising outcome that “normal” levels of wakefulness are achieved based on standard objective and subjective sleepiness tests.
Inventor(s):	Lawrence Patrick Carter, Yuan Lu, Katayoun Zomorodi
Assignee:	Axsome Malta Ltd
Application Number:	US18/316,841
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,865,098
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 11,865,098

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Axsome Malta	SUNOSI	solriamfetol hydrochloride	TABLET;ORAL	211230-001	Jun 17, 2019	AB	RX	Yes	No						TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA (OSA)
Axsome Malta	SUNOSI	solriamfetol hydrochloride	TABLET;ORAL	211230-002	Jun 17, 2019	AB	RX	Yes	Yes						TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA (OSA)

International Family Members for US Patent 11,865,098

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2018278332
Brazil	112019025286
Canada	3065522
China	111201014